BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25138167)

  • 1. Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.
    Plönes T; Beckers F; Engel-Riedel W; Stoelben E; Brockmann M; Schildgen V; Schildgen O
    BMC Res Notes; 2014 Aug; 7():549. PubMed ID: 25138167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
    Marek LA; Hinz TK; von Mässenhausen A; Olszewski KA; Kleczko EK; Boehm D; Weiser-Evans MC; Nemenoff RA; Hoffmann H; Warth A; Gozgit JM; Perner S; Heasley LE
    Mol Cancer Res; 2014 Oct; 12(10):1460-9. PubMed ID: 24966347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
    Okuda K; Sasaki H; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1105-11. PubMed ID: 18392851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
    Rena O; Boldorini LR; Gaudino E; Casadio C
    J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of actionable mutations in malignant pleural mesothelioma.
    Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
    Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
    Takeda M; Kasai T; Hatakeyama K; Nakai T; Itami H; Uchiyama T; IIzuka N; Maruyama H; Ohbayashi C
    Int J Surg Pathol; 2017 Dec; 25(8):668-673. PubMed ID: 28673192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 8. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
    Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F
    J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
    Riquelme E; Suraokar MB; Rodriguez J; Mino B; Lin HY; Rice DC; Tsao A; Wistuba II
    J Thorac Oncol; 2014 Jul; 9(7):998-1007. PubMed ID: 24926545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
    Thomas A; Lee JH; Abdullaev Z; Park KS; Pineda M; Saidkhodjaeva L; Miettinen M; Wang Y; Pack SD; Giaccone G
    J Thorac Oncol; 2014 Apr; 9(4):567-71. PubMed ID: 24736083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
    Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
    Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
    Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.